
1. drugs. 2017 may;77(8):911-921. doi: 10.1007/s40265-017-0739-8.

elbasvir/grazoprevir: review chronic hcv genotypes 1 4.

al-salama zt(1), deeks ed(2).

author information: 
(1)springer, private bag 65901, mairangi bay, auckland, 0754, new zealand.
demail@springer.com.
(2)springer, private bag 65901, mairangi bay, auckland, 0754, new zealand.

a fixed-dose combination tablet comprising hepatitis c virus (hcv) ns5a
inhibitor elbasvir hcv ns3/4a protease inhibitor grazoprevir
(elbasvir/grazoprevir; zepatier™) recently approved treatment of
chronic hcv genotype 1 4 infection eu usa. phase iii
trials, 12 16 weeks treatment once-daily elbasvir/grazoprevir
(fixed-dose tablet individual agents), taken without ribavirin,
generally provided high rates sustained virological response 12 weeks
(svr12) treatment-naive -experienced adult patients chronic hcv
genotype 1a, 1b 4 infection, including without compensated
cirrhosis, hiv co-infection, inherited blood disorders chronic kidney disease 
or patients receiving opioid agonist therapy japanese origin.
elbasvir/grazoprevir generally well tolerated. thus, elbasvir/grazoprevir,
with without ribavirin, represents effective new option treatment
of adults chronic hcv genotype 1 4 infection, including number of
difficult-to-treat populations.

doi: 10.1007/s40265-017-0739-8 
pmid: 28417245  [indexed medline]

